Pfizer, Inc. (NYSE:PFE) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 51,408,403 shares, a decline of 11.9% from the October 13th total of 58,325,639 shares. Based on an average daily trading volume, of 17,276,742 shares, the short-interest ratio is presently 3.0 days. Approximately 0.9% of the company’s shares are short sold.

In related news, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. Insiders have sold 374,621 shares of company stock valued at $12,796,098 in the last 90 days. Company insiders own 0.06% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Harwood Advisory Group LLC grew its holdings in shares of Pfizer by 29.3% during the first quarter. Harwood Advisory Group LLC now owns 13,256 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 3,005 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Pfizer by 1.7% during the first quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock valued at $1,120,704,000 after buying an additional 554,777 shares during the last quarter. BTR Capital Management Inc. grew its holdings in shares of Pfizer by 4.2% during the first quarter. BTR Capital Management Inc. now owns 246,537 shares of the biopharmaceutical company’s stock valued at $8,434,000 after buying an additional 9,977 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of Pfizer by 5.5% during the first quarter. Profund Advisors LLC now owns 369,364 shares of the biopharmaceutical company’s stock valued at $12,636,000 after buying an additional 19,312 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Pfizer by 1.2% during the first quarter. Acadian Asset Management LLC now owns 2,864,108 shares of the biopharmaceutical company’s stock valued at $97,982,000 after buying an additional 32,932 shares during the last quarter. 69.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer (PFE) opened at $35.38 on Wednesday. The stock has a market capitalization of $210,220.00, a price-to-earnings ratio of 14.07, a PEG ratio of 2.49 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer has a 12-month low of $30.51 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 earnings per share. equities research analysts anticipate that Pfizer will post 2.59 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is presently 78.53%.

A number of analysts recently issued reports on PFE shares. BMO Capital Markets reiterated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Finally, Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.48.

ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Sees Large Decrease in Short Interest” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/pfizer-inc-pfe-sees-large-decrease-in-short-interest/1703596.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.